论文部分内容阅读
目的 探讨恶性卵巢肿瘤组织中ＣＤ４４Ｖ３ 、ＣＤ４４Ｖ６ 的表达及其临床意义。方法 用免疫组织化学方法，检测４１ 例卵巢恶性肿瘤、２０ 例卵巢良性肿瘤和２１ 例正常卵巢组织中ＣＤ４４Ｖ３ 、ＣＤ４４Ｖ６ 基因蛋白的表达情况并分析相关的临床病理因素。结果 ＣＤ４４Ｖ３ 、ＣＤ４４Ｖ６ 表达阳性率恶性组显著高于良性组和正常组；有转移者ＣＤ４４Ｖ３ 、ＣＤ４４Ｖ６ 阳性率显著高于无转移者，转移灶阳性率高于原发灶；ＣＤ４４Ｖ３ 、ＣＤ４４Ｖ６ 阳性表达者近期疗效比阴性者差；ＣＤ４４Ｖ３ 、ＣＤ４４Ｖ６ 阳性表达率与病理类型、组织学级别无关。结论 ＣＤ４４Ｖ３ 、ＣＤ４４Ｖ６ 与近期疗效有关，可作为评估预后的指标。
Objective To investigate the expression of CD44V3 and CD44V6 in malignant ovarian tumor and its clinical significance. Methods Immunohistochemistry was used to detect the expression of CD44V3 and CD44V6 in 41 cases of ovarian cancer, 20 cases of benign ovarian tumors and 21 cases of normal ovarian tissue. The clinical and pathological factors were analyzed. Results The positive rates of CD44V3 and CD44V6 in malignant group were significantly higher than those in benign group and normal group. The positive rates of CD44V3 and CD44V6 in patients with metastasis were significantly higher than those without metastasis. The positive rates of metastasis were higher than those in primary tumor. The positive rates of CD44V3 and CD44V6 in recent years The curative effect was worse than the negative ones. The positive rates of CD44V3 and CD44V6 were not related to the pathological type and histological grade. Conclusion CD44V3 and CD44V6 are closely related to the curative effect and can be used as an index to evaluate the prognosis.